A study of more than 600,000 U.S. veterans found that GLP-1 medication use was associated with a 14% lower overall risk of developing substance use disorders — including alcohol, cannabis, opioid, and stimulant addiction. A separate analysis published in The BMJ in March 2026 confirmed the signal in a population-based cohort study. And the data doesn't stop at addiction: GLP-1 users also showed reduced risks of seizures, suicidal ideation, self-harm, bulimia, and psychotic disorders including schizophrenia.
These findings are reshaping the clinical narrative around GLP-1 medications. The weight loss benefit that made these drugs famous may turn out to be one of their less remarkable properties.
The Brain Mechanism
GLP-1 receptors aren't limited to your gut. They're expressed in brain areas involved in impulse control, reward, and addiction — particularly in the dopamine pathways that govern cravings and compulsive behavior. When GLP-1 medications activate these receptors, they appear to modulate the brain's reward circuitry in ways that extend well beyond appetite suppression.
This isn't as surprising as it first sounds. Appetite and addiction share neurological infrastructure. The same reward pathways that drive you to eat another slice of pizza also drive alcohol cravings, gambling impulses, and drug-seeking behavior. A medication that recalibrates reward signaling for food might naturally affect other reward-driven behaviors.
Additionally, GLP-1 medications reduce systemic inflammation and produce weight loss — both of which independently improve brain health. Chronic inflammation is implicated in depression, cognitive decline, and addiction vulnerability. Weight loss reduces inflammation, improves blood flow to the brain, and can reverse some of the metabolic damage that contributes to mood and behavioral disorders.
What the Research Actually Shows
The January 2025 study from WashU Medicine and the VA St. Louis Health Care System examined health records of 2 million veterans treated for diabetes from 2017 through 2023. Comparing veterans who took GLP-1 medications against those on traditional diabetes drugs, the researchers found:
- Addiction risk: 14% lower overall risk of substance use disorders, with benefits across alcohol, cannabis, opioid, and stimulant categories
- Cognitive health: Reduced risk of neurocognitive disorders including Alzheimer's disease and dementia
- Behavioral health: Reduced risks of seizures, suicidal ideation, self-harm, bulimia, and psychotic disorders
- Cardiovascular: 10-20% reduction in heart attack, stroke, and cardiovascular death (consistent with the SELECT trial data)
The March 2026 BMJ publication extended these findings with a population-based cohort study design, adding confidence that the association holds across broader populations beyond veterans.
Why Telehealth Platforms Aren't Talking About This
Despite the data, most GLP-1 telehealth platforms market exclusively around weight loss. The addiction and mental health benefits rarely appear in their messaging. There are several reasons for this:
FDA labeling: GLP-1 medications are approved for specific indications (diabetes, obesity, cardiovascular risk). Marketing for off-label benefits — even when supported by published research — puts platforms in regulatory crosshairs, especially after 85+ warning letters about misleading claims.
Liability concerns: Claiming addiction or mental health benefits without FDA-approved labeling opens platforms to liability if patients make treatment decisions based on those claims.
Intake screening gaps: Most telehealth platforms don't screen for addiction history during GLP-1 intake. If they marketed the addiction benefit, they'd need to build clinical infrastructure to assess and support patients seeking treatment for dual diagnoses — a complexity most platforms aren't equipped to handle.
What This Means for Your Treatment Decision
The beyond-weight-loss benefits of GLP-1 medications don't change the core treatment decision framework — you still need to meet eligibility criteria, tolerate the medication, and work with a clinician who monitors your progress. But they do add context that's worth discussing with your prescriber:
- If you have a history of substance use disorder, the addiction risk reduction data is relevant to your benefit-risk calculation
- If you have cardiovascular risk factors, the SELECT trial data showing 20% reduction in major cardiac events is FDA-labeled and well-established
- If cognitive decline or neurodegenerative disease runs in your family, the emerging data on dementia risk reduction may inform your long-term treatment planning